Comparing bupivacaine alone to liposomal bupivacaine plus bupivacaine in interscalene blocks for total shoulder arthroplasty: a randomized, non-inferiority trial
Primary result · 72-h cumulative opioid consumption (oral MME)Result — go to the resultGeometric mean difference 11.9 mg 95% CI −6.9 to 30.8Authors' conclusion
Interscalene brachial plexus blocks performed with bupivacaine alone did not demonstrate non-inferiority compared to a mixture of liposomal bupivacaine plus bupivacaine with regards to 72-hour cumulative opioid consumption following total shoulder arthroplasty.
Study context
- Population
- Patients undergoing primary total shoulder arthroplastycompleted the study
- Participants
- 76 patients
- Comparison
- Bupi vs LB
- Bupin = 38
- LBn = 38reference
- Primary endpoint
- Cumulative postoperative opioid consumption (oral morphine equivalents); non-inferiority margin 22.5 mg
- Follow-up
- Up to 72 hours
Methodological detailsnon-inferiority, 1:1 randomisation, ultrasound-guided single-injection interscalene block
- Non-inferiority
- 1:1 randomisation
- Ultrasound-guided single-injection interscalene block
Primary result
72-h cumulative opioid consumption (oral MME)
Geometric mean difference
11.9 mg
95% CI −6.9 to 30.8
Interscalene block with bupivacaine alone vs liposomal bupivacaine plus bupivacaine
geometric mean difference 11.9 mg (95% CI −6.9 to 30.8)
As reported in the abstract
Secondary outcomes
Pain scores, patient satisfaction with analgesia, patient-reported duration of sensory block
- No meaningful differences between groups
Original publication
Comparing bupivacaine alone to liposomal bupivacaine plus bupivacaine in interscalene blocks for total shoulder arthroplasty: a randomized, non-inferiority trial. Reg Anesth Pain Med. Published 19 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →